Abstract
IN the course of treatment of leukaemia L1210 in mice using an antifolate compound, methotrexate (MTX), the leukaemic cells are affected early during treatment and later, while becoming resistant1, show impaired retention and decreased permeability to the drug2–4. Some antifolate-resistant sub-lines of leukaemia .L1210 have substantial dihydrofolate reductase (1.5.1.3) (DHR) activities5–7 and use NADPH to reduce folate to tetrahydrofolate8,9. Some authors have therefore considered the possibility of using the level of DHR activity to measure the effectiveness of the action of a drug on MTX-resistant leukaemic cells10,11. The extent to which the capacities to synthesize NADP and NADPH are influenced by the antifolate treatment is, however, unknown. Waravdekar et al.12 reported that livers of mice bearing various transplantable tumours showed impaired capacities to synthesize NAD. Furthermore, differences in the ratio of NAD to NADH2 are known to reflect the extent of oxidative metabolism and reductive synthesis in the livers of different species13. In the present experiments, the effects of daily treatment with MTX on hepatic and splenic NAD kinase (2.7.1.23) were examined in mice implanted with leukaemia L1210.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Law, L. W., Cancer Res., 16, 698 (1956).
Fischer, G. A., Biochem. Pharmacol., 11, 1233 (1962).
Werkheiser, W. C., Cancer Res., 23, 1277 (1963).
Bertino, J. R., Cancer Res., 23, 1286 (1963).
Hakala, M. T., Zakrzewski, S. F., and Nichol, C. A., J. Biol. Chem., 236, 952 (1961).
Friedkin, M., Crawford, E. J., and Misra, D., Cancer Res., 22, 600 (1962).
Roberts, D., Wodinsky, I., and Hall, T. C., Cancer Res., 25, 1899 (1965).
Werkheiser, W. C., J. Biol. Chem., 236, 888 (1961).
Misra, D. K., Humphreys, S. R., Friedkin, M., Goldin, A., and Crawford, E. J., Nature, 189, 39 (1961).
Humphreys, S. R., Thomas, L. B., Chirigos, M. A., Goldin, A., Crawford, E. J., and Friedkin, M., Nature, 195, 453 (1962).
Narurkar, M. V., Mead, J. A. R., Greenberg, N. H., Venditti, J. M., and Goldin, A., Proc. Amer. Assoc. Res., 4, 47 (1963).
Waravdekar, V. S., Powers, O. H., and Leiter, J., Proc. Soc. Exp. Biol. and Med., 92, 797 (1956).
Caiger, P., Morton, R. K., Filsell, O. H., and Jarrett, I. G., Biochem. J., 85, 351 (1962).
Friedkin, M., Crawford, E., Humphreys, S. R., and Goldin, A., Cancer Res., 22, 600 (1962).
Wang, T. P., Methods in Enzymology, 2, 652 (New York, Academic Press, Inc., 1955).
Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J., J. Biol. Chem., 193, 265 (1951).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MHATRE, R., SASLAW, L. & WARAVDEKAR, V. Effect of Methotrexate on NAD Kinase Activity in Leukaemic Mice. Nature 214, 926–927 (1967). https://doi.org/10.1038/214926a0
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1038/214926a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.